Combined p53 and retinoblastoma protein detection identifies persistent and regressive cervical high-grade squamous intraepithelial lesions

American Journal of Surgical Pathology

Volumn 29, Issue 8, 2005, Pages 1062-1066

  Baak, Jan P A ^a,b,c   Kruse, Arnold Jan ^a   Garland, Suzanne M ^d,e   Skaland, Ivar ^a   Janssen, Emiel A M ^a   Tabrizi, Sepehr ^d,e   Fagerheim, Siri ^a   Robboy, Stanley ^f   Nilsen, Stein Tore ^a  

^a STAVANGER UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF BERGEN   (Norway)

^c VU UNIVERSITY AMSTERDAM   (Netherlands)

^d ROYAL WOMEN'S HOSPITAL   (Australia)

^e UNIVERSITY OF MELBOURNE   (Australia)

^f DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Cervix; High grade squamous intraepithelial lesion; High risk human papillomavirus genotype; p53; Regression; Retinoblastoma protein

Indexed keywords

CYCLIN D1; KI 67 ANTIGEN; PROTEIN P53; RETINOBLASTOMA PROTEIN;

ADULT; ARTICLE; CANCER REGRESSION; CARCINOMA IN SITU; CELL CYCLE; CELL DIFFERENTIATION; CELL PROLIFERATION; FEMALE; GENOTYPE; HISTOPATHOLOGY; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; SQUAMOUS CELL CARCINOMA; TUMOR BIOPSY; UTERINE CERVIX CANCER; WART VIRUS;

ADULT; BIOPSY; CARCINOMA IN SITU; CYCLIN D1; CYCLIN-DEPENDENT KINASE INHIBITOR P16; EPITHELIUM; FEMALE; FOLLOW-UP STUDIES; HUMANS; KI-67 ANTIGEN; PAPILLOMAVIRIDAE; RETINOBLASTOMA PROTEIN; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53; UTERINE CERVICAL NEOPLASMS;

EID: 22944482221     PISSN: 01475185     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Baak JP. The framework of pathology: good laboratory practice by quantitative and molecular methods. J Pathol. 2002;198:277-283.
2. Balsitis SJ, Sage J, Duensing S, et al. Recapitulation of the effects of the human papillomavirus type 16 E7 oncogene on mouse epithelium by somatic Rb deletion and detection of pRb-independent effects of E7 in vivo. Mol Cell Biol. 2003;23:9094-9103.
3. Bosch FX, Manos MM, Munoz N, et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. J Natl Cancer Inst. 1995;87:796-802.
4. Bosch FX, Lorincz A, Munoz N, et al. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol. 2002;55:244-265.
5. Dennerstein GJ, Scurry JP, Garland SM, et al. Human papillomavirus vulvitis: a new disease or an unfortunate mistake? Br J Obstet Gynaecol. 1994;101:992-998.
6. Dyson N, Howley PM, Munger K., et al. The human papillomavirus 16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science. 1989;23:934-939.
7. Ferlay J, Bray F, Pisani P. Globocan 2000: Cancer incidence, Mortality and Prevalence Worldwide. Lyon, France: IARC Press, 2001.
8. Fonseca-Moutinho JA, Cruz E, Carvalho L, et al. Estrogen receptor, progesterone receptor, and bcl-2 are markers with prognostic significance in CIN III. Int J Gynecol Cancer. 2004;14:911-920.
9. Gravitt PE, Peyton CL, Alessi TQ, et al. Improved amplification of genital human papillomaviruses. J Clin Microbiol. 2000;38:357-361.
10. Hall PA, Going JJ. Predicting the future: a critical appraisal of cancer prognosis studies. Histopathology. 1999;35:489-494.
11. Keating JT, Cviko A, Riethdorf S, et al. Ki67, cyclin E, and p16INK4 are complimentary surrogate biomarkers for human papilloma virus-related cervical neoplasia. Am J Surg Pathol. 2001;25:884-891.
12. Kruse AJ, Baak JPA, de Bruin PC, et al. Ki67 immunoquantitation in cervical intraepithelial neoplasia (CIN): a sensitive marker for grading. J Pathol. 2001;193:48-54.
13. Kruse AJ, Skaland J, Janssen EA, et al. Quantitative molecular parameters to identify low-risk and high-risk early CIN lesions: role of markers of proliferative activity and differentiation and Rb availability. Int J Gynecol Pathol. 2004;23:100-110.
14. Nucci MR, Castrillon DH, Bai H, et al. Biomarkers in diagnostic obstetric and gynecologic pathology: a review. Adv Anat Pathol. 2003;10:55-68.
15. Ostor AG. The natural history of cervical intraepithelial neoplasia: a critical review. Int J Gynecol Pathol. 1993;12:186-192.
16. Resnick RM, Cornelissen MT, Wright DK, et al. Detection and typing of human papillomavirus in archival cervical cancer specimens by DNA amplification with consensus primers. J Natl Cancer Inst. 1990;82:1477-1484.
17. Scheffner M, Werness BA, Huibregtse JM. The E 6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell. 1990;63:1129-1136.
18. Wang JL, Zheng BY, Li XD, et al. Predictive significance of the alterations of p16INK4A, p14ARF, p53, and proliferating cell nuclear antigen expression in the progression of cervical cancer. Clin Cancer Res. 2004; 10:2407-2414.
19. Zielinsky GD, Snijders PJF, Rozendaal L, et al. The presence of high-risk HPV combined with specific p53 and p16ink4a expression patterns points to high-risk HPV as the main causative agent for adenocarcinoma in situ and adenocarcinoma of the cervix. J Pathol. 2003;201:535-543.